C2603343||study
C0762662||rofecoxib
C0044576||1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
C0023768||bilayer
C0687133||interactions
C0762662||rofecoxib
C0044576||1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
C0044576||(1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine)
C0023768||bilayer
C2603343||studied
C0025663||method
C0044576||1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
C0023768||bilayer
C0762662||rofecoxib
C1254351||drug
C0762662||rofecoxib
C0044576||1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
C0023768||bilayer
C0026344||model
C0023768||bilayer
C0205099||center
C0044576||1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
C0023768||bilayer
C0205099||central
C0028778||barrier
C0023768||bilayer
C1254351||drug
C0278250||favorable
C0762662||rofecoxib
C0023768||bilayer
C0023768||bialyer
C0205099||center
C0936012||analysis
C0762662||rofecoxib
C0762662||rofecoxib
C0762662||rofecoxib
C0026344||model
C0026344||model